South Korea Semaglutide Market Size, Share, and COVID-19 Impact Analysis, By Product (Ozempic, Wegovy, and Rybelsus), By Application (Type 2 Diabetes Mellitus and Obesity), By Route of Administration (Parental and Oral), and South Korea Semaglutide Market Industry Trend, Forecasts to 2035

South Korea Semaglutide Market Insights Forecasts to 2035

• The South Korea Semaglutide Market Size Was Estimated at USD 195.34 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 14.54% from 2025 to 2035
• The South Korea Semaglutide Market Size is Expected to Reach USD 869.46 Million by 2035

According to a Research Report Published by Spherical Insights & Consulting, The South Korea Semaglutide Market Size is anticipated to Reach USD 869.46 Million by 2035, Growing at a CAGR of 14.54% from 2025 to 2035. The growing incidence of type 2 diabetes and obesity, the need for GLP-1 receptor agonists, and the expanding use of weight-loss therapies are the main factors driving the semaglutide market.

Market Overview

The Semaglutide Market Size focuses on the production and sale of semaglutide-based medications, primarily used to treat type 2 diabetes and obesity by regulating blood sugar and appetite. The effective glycemic control, weight loss, and reduced cardiovascular risks, improving patient quality of life. Growing diabetes and obesity prevalence creates vast market opportunities, especially with rising patient awareness and acceptance of advanced therapies. Innovations in oral and injectable formulations expand treatment options. Governments support the market through healthcare policies, reimbursement schemes, and public health initiatives aimed at managing chronic diseases. These efforts, coupled with increasing healthcare infrastructure and research investments, drive the semaglutide market’s robust growth and accessibility across various regions.

Report Coverage

This research report categorizes the market for South Korea semaglutide market based on various segments and regions, forecasts revenue growth, and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea semaglutide market. Recent market developments and competitive strategies such as expansion, product launch, development, partnership, merger, and acquisition, have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment South Korea semaglutide market.

Driving Factors

The rising prevalence of type 2 diabetes and obesity worldwide, increasing the demand for effective and safe treatment options. Strong clinical evidence demonstrating semaglutide’s benefits in glycemic control and weight management boosts adoption. Growing patient awareness, improved healthcare infrastructure, and favorable reimbursement policies further support market expansion. Additionally, innovations in oral and injectable formulations enhance patient convenience and compliance

Restraining Factors

The high treatment costs and limited insurance coverage, which restrict patient access in some regions. Side effects like nausea and gastrointestinal issues may reduce patient compliance. Competition from alternative diabetes and obesity therapies also limits market growth. Additionally, regulatory hurdles and lengthy approval processes can delay new product launches. Limited awareness in certain markets and concerns about long-term safety.

Market Segmentation

The South Korea semaglutide market share is classified into product, application, and route of administration.

• The Ozempic segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea semaglutide market is segmented by product into Ozempic, wegovy, and rybelsus. Among these, the Ozempic segment held a significant share in 2024 and is expected to grow at a substantial CAGR during the forecast period. Its proven effectiveness in managing type 2 diabetes and growing off-label use for weight management. Its established brand presence, strong clinical support, and physician preference contribute to high adoption. Additionally, patient awareness and reimbursement policies favor Ozempic, boosting accessibility. Continuous innovation in dosing and delivery also enhances user convenience

• The type 2 diabetes mellitus segment held a significant share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea semaglutide market is segmented by application into type 2 diabetes mellitus and obesity. Among these, the type 2 diabetes mellitus segment dominated a share in 2024 and is expected to grow at a significant CAGR during the forecast period. The rising diabetes prevalence and strong clinical evidence supporting semaglutide’s effectiveness in glycemic control. Government healthcare policies and insurance coverage prioritize diabetes management, increasing patient access to semaglutide. Moreover, growing physician awareness and patient preference for advanced treatment options contribute to higher adoption.

• The parentral segment dominated a share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The South Korea semaglutide market is segmented by route of administration into parental and oral. Among these, the parenteral segment dominated a share in 2024 and is expected to grow at a significant CAGR during the forecast period. Its established efficacy and faster absorption compared to oral forms. Injectable semaglutide, like Ozempic, is widely prescribed for type 2 diabetes and obesity management, supported by strong clinical data. Patient familiarity and physician preference for proven injectable treatments further drive demand. Additionally, limited availability and lower adoption of oral semaglutide contribute to the dominance of the parenteral route, ensuring significant growth during the forecast period.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea semaglutide market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the companies' current news and developments, including product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Hanmi Pharmaceutical
• Chong Kun Dang Pharmaceutical Corp.
• Samsung Biologics 
• LG Chem (LG Life Sciences)
• Daewoong Pharmaceutical
• GC Biopharma (Green Cross Corporation)
• Yuhan Corporation
• SK Biopharmaceuticals
• Hanall Biopharma
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the South Korea semaglutide market based on the below-mentioned segments:

South Korea Semaglutide Market, By Product

• Ozempic
• Wegovy
• Rybelsus

South Korea Semaglutide Market, By Application

• Type 2 Diabetes Mellitus
• Obesity

South Korea Semaglutide Market, By Route Of Administration

• Parenteral
• Oral